LEMAITRE VASCULAR INC — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
LeMaitre Vascular (LMAT, $1.7B market cap) reported Q2 2026 net sales of $70.4M (+10% YoY, +10% organic), gross margin 72.1% (+210 bps), operating income $20.4M (+26%), and diluted EPS $0.74 (+23%). Artegraft sales surged 34%; Grafts, carotid shunts, and patches each hit records. The company raised full-year 2026 guidance to sales $274.3M–$278.3M (midpoint +11% organic) and operating income $75.3M–$78.2M (midpoint +13% GAAP, +19% adjusted). Board approved a $0.25/share quarterly dividend and a $100M share repurchase authorization (through February 2027).
Why this rating
Solid organic growth, margin expansion, and Artegraft momentum are encouraging; guidance raise affirms trajectory. However, ~$70M quarterly sales is typical for a $1.7B company; event is meaningful but not transformational.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.